← Back to Dashboard
HR-7871House2026-03-09Health

MVP Act

YourVoice.Now Summary

Drug companies and state Medicaid programs could enter "value-based purchasing arrangements" — essentially pay-for-performance deals where the price of an expensive medication depends on how well it actually works for patients. Right now, the way Medicaid calculates drug prices makes these deals complicated and sometimes financially impractical. This bill would fix that by letting manufacturers report multiple "best price" points for the same drug depending on patient outcomes, and by excluding refunds tied to treatment failures from average price calculations. It also provides an exception from anti-kickback rules for these arrangements and requires a GAO study on whether the deals are improving access and lowering costs.

Congressional Summary

Medicaid VBPs for Patients Act or the MVP ActThis bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.

Details

Congress
119th
Chamber
House
Status
summarized
Action
Introduced in House
Action Date
2026-03-09
Date Added
2026-03-30